Salta al contenuto principale
Farmacovigilanza
Form di ricerca
Ricerca
Home
Rivista
Casi
Newsletter
Link
Chi siamo
Contatti
News
Dicembre 2021
Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
Novembre 2021
Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
Novembre 2021
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Novembre 2021
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial
Ottobre 2021
Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021
Ottobre 2021
Surveillance for Adverse Events After COVID-19 mRNA Vaccination
Ottobre 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Settembre 2021
No Correlation between Anti-PF4 and Anti–SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination
Settembre 2021
Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2
Settembre 2021
Surveillance for Adverse Events After COVID-19 mRNA Vaccination
Pagine
« prima
‹ precedente
…
2
3
4
5
6
7
8
9
10
…
seguente ›
ultima »
80.211.154.110
